Allogene Therapeutics Ownership
| ALLO Stock | USD 2.07 0.01 0.49% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 190 M | Current Value 209.2 M | Avarage Shares Outstanding 128.4 M | Quarterly Volatility 37.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Allogene |
Allogene Stock Ownership Analysis
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 1.55. The entity had not issued any dividends in recent years. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people. For more info on Allogene Therapeutics please contact the company at 650 457 2700 or go to https://www.allogene.com.Besides selling stocks to institutional investors, Allogene Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Allogene Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Allogene Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Allogene Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Allogene Therapeutics Insider Trades History
About 17.0% of Allogene Therapeutics are currently held by insiders. Unlike Allogene Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Allogene Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Allogene Therapeutics' insider trades
Allogene Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Allogene Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allogene Therapeutics backward and forwards among themselves. Allogene Therapeutics' institutional investor refers to the entity that pools money to purchase Allogene Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 3.2 M | Wildcat Capital Management, Llc | 2024-09-30 | 2.9 M | Two Sigma Investments Llc | 2024-09-30 | 2.8 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.7 M | Perceptive Advisors Llc | 2024-09-30 | 2.7 M | Two Sigma Advisers, Llc | 2024-09-30 | 2.4 M | Goldman Sachs Group Inc | 2024-09-30 | 2.2 M | Vida Ventures Advisors, Llc | 2024-09-30 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.7 M | Fmr Inc | 2024-09-30 | 30 M | Tpg Gp A, Llc | 2024-09-30 | 18.7 M |
Allogene Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allogene Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allogene Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allogene Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allogene Therapeutics Outstanding Bonds
Allogene Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Allogene Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Allogene bonds can be classified according to their maturity, which is the date when Allogene Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Allison Transmission 5875 Corp BondUS019736AF46 | View | |
| US019736AG29 Corp BondUS019736AG29 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Allison Transmission 475 Corp BondUS019736AE70 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Allogene Therapeutics Corporate Filings
F4 | 10th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 4th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.66 | DYAI | Dyadic International | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.